Trial Profile
A Phase II Randomised, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of Oral NP202 in Adults who have Paroxysmal Atrial Fibrillation and a Cardiac Device
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Oct 2018
Price :
$35
*
At a glance
- Drugs NP 202 (Primary)
- Indications Paroxysmal atrial fibrillation
- Focus Therapeutic Use
- Acronyms NP202-AF
- Sponsors Armaron Biosciences
- 18 Oct 2018 New trial record